Biofrontera (NASDAQ:BFRI) Upgraded by Wall Street Zen to “Buy” Rating

Wall Street Zen upgraded shares of Biofrontera (NASDAQ:BFRI) from a hold rating to a buy rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

Other analysts also recently issued reports about the company. Weiss Ratings upgraded Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Zacks Research upgraded shares of Biofrontera from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold”.

Biofrontera Stock Performance

NASDAQ BFRI opened at $1.55 on Friday. The business’s 50 day moving average price is $1.30 and its 200-day moving average price is $1.07. Biofrontera has a fifty-two week low of $0.55 and a fifty-two week high of $1.66. The company has a market cap of $23.02 million, a P/E ratio of -3.44 and a beta of 0.83. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.08 and a current ratio of 1.18.

Biofrontera (NASDAQ:BFRI) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05. Biofrontera had a negative net margin of 13.78% and a negative return on equity of 145.81%. The company had revenue of $12.00 million for the quarter, compared to analyst estimates of $9.50 million. Sell-side analysts predict that Biofrontera will post -0.6 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Biofrontera stock. Geode Capital Management LLC boosted its position in shares of Biofrontera Inc. (NASDAQ:BFRI) by 54.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 65,677 shares of the company’s stock after purchasing an additional 23,074 shares during the quarter. Geode Capital Management LLC owned about 0.56% of Biofrontera worth $37,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 10.08% of the company’s stock.

Biofrontera Company Profile

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.